同得仕(集团)(00518.HK)出售升阳股份备忘录终止 仍在进行商业磋商
格隆汇9月9日丨同得仕(集团)(00518.HK)公布,2019年7月11日,公司与潜在买方订立谅解备忘录,内容有关公司建议出售公司直接全资附属公司升阳(海外)有限公司的全部股份。
于2019年8月26日,公司与潜在买方订立补充协议以延长排他期至2019年9月9日或订约方可能书面协定的其他较后日期。
于公告日期,公司并无就可能出售事项与潜在买方订立具法律约束力的协议。因此,谅解备忘录终止,排他期于2019年9月9日届满。尽管排他期届满,但公司与潜在买方之间就可能出售事项进行的商业磋商仍在进行中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.